Stock News Staff

NASDAQ:IDRA

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Moves Higher

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock has apparently come under selling pressure at the end of the last five trading sessions. Even so, IDRA stock saw a 11.5% increase over the past week. Friday’s high of $1.83 was 38% higher than the 52-week low of $1.32 which was recently established on October 26, 2017.

IDRA stock had plummeted on October 26, after Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced pricing a share offering at $1.50 – the previous close for IDRA shares was $2.03. The offering was for 33,333,334 shares of its common stock with a 30-day option to for the underwriters to purchase up to an additional 5,000,000 shares of common stock.

NASDAQ:IDRA

About Idera

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s development program focuses on boosting the immune system to play a more powerful role in fighting cancer, and ultimately increase the number of people who can benefit from immunotherapy. Idera invests in research and development, and works with investigators and partners to address the unmet needs of patients who are suffering from rare, life-threatening diseases.

IDRA Stock Performance

JP Morgan, Wedbush Securities, Piper Jaffray, and Baird all follow Idera Pharmaceuticals Inc (NASDAQ:IDRA) and rate the shares as a “Strong Buy”. The listed consensus one-year price target is $5.75. Year-to-date ODRA shares are up only 16%. For the year, IDRA stock is up 19.2%.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has posted per share losses since 2012 (-$0.81) but the trend has been favorable and the loss for 2016 was just (-$0.30). Last year the company posted their first significant sales figure of $16.2 million. The downside for investors has been the annual dilution as outstanding shares have increased every year since 2012 when the number of outstanding shares was 27.64 million. But by the end of 2016, and prior to the most recent share offering, over 127.6 million shares were listed as outstanding.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Rand Logistics, Inc. (NASDAQ:RLOG)

Rand Logistics, Inc. (NASDAQ:RLOG) Starting a Rebound?

Rand Logistics, Inc. (NASDAQ:RLOG)

Rand Logistics, Inc. (NASDAQ:RLOG), headquartered in Jersey City, New Jersey, offers bulk freight shipping services throughout the U.S. Great Lakes region. Through its subsidiaries, the Rand Logistics operates ten self-unloading bulk carriers, including eight River Class vessels and one River Class integrated tug/barge unit, and three conventional bulk carriers.

Rand Logistics, Inc. (NASDAQ:RLOG)

Rand Logistics Competitive Advantage

Rand Logistics, Inc. (NASDAQ:RLOG) has a competitive advantage that is rooted in U.S. and Canadian legislation. Due to the provisions of the Jones Act and the Canadian Marine Act, Rand Logistics is the only ship carrier able to offer significant domestic port-to-port services in both Canada and the U.S. on the Great Lakes. The Jones Act mandates that only ships that are built, crewed, and owned by U.S. citizens can operate between U.S. ports. The Canada Marine Act requires Canadian commissioned ships to operate between Canadian ports.

RLOG stock has not traded above $1 since mid-February, 2017. Technically, this puts the company in violation of NASDAQ Rule 5550(a)(2) which states that “(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share.”

Year-to-date, RLOG shares have lost over 50% of their value. But in the last quarter, shares have rebounded and gained almost 45%. The stock’s 52-week low of $0.19 was established in July.

While RLOG stock has rebounded recently, some observers still believe there are issues with the finances that will be very challenging for the company to overcome. According to published accounts, Rand Logistics, Inc. (NASDAQ:RLOG) has a current ratio of 0.10. The current ratio measures whether or not a firm has enough resources to cover its debts over the next year. When a current ratio is below 1, then the company may have problems meeting its short-term obligations (current liabilities).

However, reports show that at least one person with a large (10+%) stake in the company has been purchasing shares since early August. The consensus, one-year price target for RLOG is $2.00.

Sales took a big hit for FY2017 when the company reported a figure of $115.5 million – well below the 2016 figure of $148.4 million. FY2017 was also the largest per share loss the company has posted since 2012. For FY2017 they reported a loss of (-$1.08) – more than treble the loss of 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RLOG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc (NASDAQ:GNMK) Tumbles

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc (NASDAQ:GNMK) shares shed over 40% of their value in Friday’s trading session after the company reported a (-$15.4) million loss, or (-$0.28) per share, for Q3 2017. Those results were in line with analyst expectations but revenues, $11.6 million, were 18% lower than what the street was expecting. GNMK shares ended the day at $4.26 on heavy volume. A stock that normally trades under 400,000 shares per day traded over seven million shares by Friday’s end of trading.

GenMark Diagnostics, Inc (NASDAQ:GNMK)

Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) experienced similar price action when they released their Q2 earnings results this past summer. The market responded to those losses by selling off the stock to the tune of 15%. At the time, shares were trading around the $10 handle. Since then, shares steadily slid to $8 before they gapped down over 40% on Thursday’s earning’s announcement.

Carlsbad, CA-based GenMark Diagnostics, Inc (NASDAQ:GNMK) is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and assist healthcare providers in determining the most efficient patient treatment. GenMark’s proprietary eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a workstation and self-contained, disposable test cartridges.

GenMark Stock

A frequent characteristic of biotech shares that dramatically underperform is the continual issuance of new shares which leads to a dilution of shareholder equity. In Genmark’s case that dilution has not been a major concern. In 2014, there were 41.35 million GNM shares outstanding. That number increased to just 44.1 million by the end of 2016. Even sales are trending upwards. For 2012, the company reported $20.5 million in sales. By 2016 that number was a robust $49.3 million.

However, GenMark Diagnostics, Inc (NASDAQ:GNMK) management has been unable to translate increasing sales into shareholder profits. Per share, the company lost (-$0.84) in 2012. That figure was followed by annual per share losses of (-$0.95), (-$0.93), (-$1.00), and, for 2016, (-$1.15). Year-to-date GNMK shares are down over 65% and have lost over 55% in the last month. That share performance is reflected in the stock’s Relative Strength Index (RSI) score of 9.7. Most observers believe that an RSI below 20 is signaling an “Oversold” condition.

Many sector observers believe that the share drop will force the Board of Directors for GenMark Diagnostics, Inc (NASDAQ:GNMK) to investigate a licensing agreement, merger, or sale in an effort to generate shareholder value.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GNMK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Q3 Earnings Beat Estimates

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 9.09% despite the company posting better than expected third quarter financial results. The clinical-stage immunotherapy company reported a net loss of (-$13.4) million or (-$0.52) cents a share. Analyst were expecting a net loss of (-$0.63) cents a share.

Immune Design Corp (NASDAQ:IMDZ)

Q3 Financial Results

Investor confidence in Immune design has taken a hit in recent weeks, seen by the stock trading near all-time lows. The stock is down by more than 50% for the year.

Immune Design Corp (NASDAQ:IMDZ) posted revenues of $0.5 million for the three months ended September 30, 2017. The revenue is primarily attributable to collaboration revenues associated with the Sanofi G103 HSV vaccine product collaboration.

However, it was a decline from revenues of $8.2 million reported last year. Revenue for the corresponding period last year included $7 million in license revenue and $0.4 million in product sales associated with the Sanofi collaboration.

Revenue for the first six months of the year totaled $6.7 million down from $11.2 million for the corresponding period last year. Research and Development expenses in the third quarter totaled $10.2 million compared to $11.2 million for the corresponding period last year. The decrease was primarily attributed to a decline in licensing royalties and fees to other third parties.

Immune Design Corp (NASDAQ:IMDZ) exited the third quarter with cash and cash equivalent of $67.5 million compared to $110.4 million as of December 31, 2016.

Pipeline Development

During the quarter, Immune Design Corp (NASDAQ:IMDZ) achieved an important milestone in the development of its drug pipeline. The FDA approved the Phase 3 trial, design, and approval criteria for the company’s candidate drug for the treatment of synovial sarcoma, CMB305.

“In addition, at ESMO we presented interim analysis data from our ongoing randomized Phase 2 study of CMB305 and atezolizumab showing that patients receiving the combination therapy experienced greater clinical benefit and immune response than those receiving atezolizumab alone,” said CEO, Carlos Paya.

Immune Design Corp (NASDAQ:IMDZ) completed an underwritten follow-on public offering in Q3 that resulted in the sale of 22.4 million shares of common stock. Estimated net proceeds from the offering is $86.6 million. The company plans to use net proceeds from the offering to fund ongoing clinical programs and for working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

VIVUS, Inc. (NASDAQ:VVUS) New Lows

VIVUS, Inc. (NASDAQ:VVUS)

Campbell, CA-based VIVUS, Inc. (NASDAQ:VVUS) has established new lows for three days in a row on the back of higher than average volume. In August, the street expected VIVUS, Inc. (NASDAQ:VVUS) to report a Q2 2017 loss of (-$0.13) and that was exactly what occurred. But revenues tumbled almost 19%, to $11.2 million.

VIVUS, Inc. (NASDAQ:VVUS)

In mid-August, VVUS stock broke below the psychologically important $1 per share level and touched $0.86 on September 6. Shares then proceeded to trade higher near the $1 level before tumbling for 13 of the next 15 trading days. Today the shares touched an all-time low of $0.61.

VIVUS Business

VIVUS, Inc. (NASDAQ:VVUS) is a biopharmaceutical company. It develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. Qsymia has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases.

VVUS Stock Performance

Unlike many biotechnology companies, VIVUS, Inc. (NASDAQ:VVUS) has not diluted shareholder equity through additional public share offerings. However its revenues have been inconsistent. In 2013, the company reported sales of $114.2 million followed by annual sales of $95.4 million, and $124.3 million for 2016.

Earnings have been more of a bright spot for the company. From 2012 until 2015, VIVUS, Inc. (NASDAQ:VVUS) reported losses, but for 2016 the company reported a per share profit of $0.22.

VVUS stock has a consensus one-year target price of $2.15. For the year, and prior to today’s price action, the stock has lost almost 35%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VVUS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Buyers Jump into Leading Brands, Inc (USA) (NASDAQ:LBIX)

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Shares of Leading Brands, Inc (USA) (NASDAQ:LBIX) are up over 50% and reversing the stock’s ten day decline following the company’s earnings announcement for Q2 2017. Observers believe the market is viewing the previous sell-off as overdone. Investors are buying in abnormally large quantities and the stock’s volume is on pace to register a number 20 times the listed daily average.

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Leading Brands, Inc (USA) (NASDAQ:LBIX), headquartered in Vancouver, BC, Canada, and its subsidiaries develop, market, and distribute their own line of branded beverage products. These include TrueBlue, PureBlue, and LiveHappy Water.

Leading Brands Q2 Earnings

On October 16, 2017 Leading Brands, Inc (USA) (NASDAQ:LBIX) announced a $710,000 (-$0.25 per share) net loss from continuing operations versus a net loss of $949,000 (or $0.33 per share) in Q2 2016. Gross revenue for continuing operations for Q2 2017 was $510,000, versus $568,000 in the comparable period of last year. Gross profit margin for the quarter was 0.7%, up from (9.1%) in the same quarter last year.

LBIX Stock Reaction

On October 10, 2017, investors began accumulating shares, reportedly in anticipation of the earnings announcement. Shares boomed from $0.84 to $3.75 on October 13. The day of the announcement, shares reached $3.20 but closed at $2.82.

The failure to sustain the share increase led to a continuous decline. By October 31, LBIX stock hit a daily low of $1.30 – a 65% drop from its October 13 high. But today, investors jumped in and sent LBIX shares back up. They opened at $1.49 and have hit an inter-day high of $2.52. LBIX stock is trading around $2.25 at the time of this writing (11:52 AM EST).

Leading Brands Sales and Earnings History

In 2013, the company posted a per share profit of $0.15 and followed it up the next year with a figure of $0.31. Unfortunately, the next three years have seen losses. For 2015 the per share loss was (-$1.02), then a loss of (-$1.06) for 2016, and a loss of (-$0.86) for FY2017.

Sales have suffered as well. In 2013 sales were reported at $13.4 million and 2014 saw sales of $11.9 million. But in 2015 sales were just $400,000, then the next year just $600,000, and $900,000 for FY2017.

The one-year consensus price target amongst analysts is $4.40.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LBIX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) Drops After Q3 Net Loss

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

Shares of Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) fell 3.4% after the pharmaceutical company reported a (-$2) million net loss. Basic and diluted net loss for the three months ended September 30, 2017, came in at (-$0.14) a share, compared to net loss of (-$0.41) reported last year.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

RTTR Stock Performance

Despite a 42% year-over-year decrease in net loss, investors still pushed the stock lower in the market. Ritter Pharmaceuticals has underperformed the overall industry for the better part of the year. The stock is down by more than 80% for the year.

In defense of the company’s performance, Chief Executive Officer, Michael D. Step said they are committed and focused on the development of RP-G28, for the treatment of lactose intolerance. Plans are already underway to commence Phase 3 trials after a productive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).

RP-G28 Trials

During the quarter, Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) raised $23 million in an underwritten public offering. Net proceeds from the offering are to be used to finance the proposed Phase 3 trial in the first half of next year. The therapy has the potential to become the first FDA approved treatment for Lactose intolerance.

“With Phase 3 guidance from the FDA from our End of Phase 2 Meeting and our recent successful capital raise behind us, we have a clear regulatory pathway and we have sufficient funding to execute the first pivotal Phase 3 clinical trial of RP-G28 through data readout,” said Andrew J. Ritter President Ritter Pharmaceutical.

Ritter Pharmaceuticals Operating Costs

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)’s research and development expenses in the quarter totaled $0.9 million primarily attributable to Phase 2b/3 extension study fees of RP-G28 on Phase 3 program planning expenses. However, it was a decline from $2.3 million spent last year.

Total operating expenses in the quarter stood at $2 million compared to $3.5 million reported last year. The decrease was primarily as a result of a decrease in research and development expenses. Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) exited the quarter with cash and cash equivalent of $3.6 million. The cash balance also received a boost of $21 million from a public offering held last month.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RTTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Drops After Pricing Offering

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares fell 14.7% after announcing the pricing of a previously announced public offering of 9 million shares on the Tel-Aviv Stock Exchange. The developer of placenta-based cell therapy products has priced the offering at $1.67 a share and expects gross proceeds of $15.1 million.

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

PSTI Investors Reaction

The accepted orders in the aggregate amount of $15.1 million after the offering became over-subscribed. The minimum share price consequently increased from $1.61 to $1.67 a share. The offering should close on or about December 31, 2017.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) plans to use net proceeds from the offering for research and product development. Part of the funds will also to be used to finance clinical trial activities, working capital, and for other general corporate purposes.

Investors reacted to the public offering pricing by pushing the stock lower. A point of concern is that the public offering was priced at a discount and that it could lead to further dilution of the stock. However, the stock continues to trade in an uptrend. The stock is up by more than 10% for the year.

PLX-R18 Development

The pricing of the public offering follows the Israel’s Ministry of Health approval of the company’s Phase 1 study of drug candidate PLX-R18. Pluristem Therapeutics Inc. (NASDAQ:PSTI) is investigating the drug candidate for the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation HCT. The U.S. Food and Drug Administration (FDA) has also approved the trial. In the United States, Pluristem is to recruit up to 30 patients for the trial.

“We’re very pleased with the Israeli Ministry of Health’s vote of confidence in our innovative therapies and efforts to provide treatments for a range of hematopoietic conditions, including insufficient recovery from hematopoietic stem cell transplants,” stated Zami Aberman, Pluristem Co-CEO, and Chairman

In addition, PLX-R18 is in late-stage development as a treatment for acute radiation syndrome (ARS). The cell therapy is designed to treat bone marrow that is unable to produce enough blood cells due to ARS. Pluristem Therapeutics Inc. (NASDAQ:PSTI) holds several patents that cover PLX-r18 for the treatment of impaired hematopoietic systems in case of a bone marrow transplant.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Supercom Ltd (NASDAQ:SPCB)

New Highs for Supercom Ltd (NASDAQ:SPCB)

Supercom Ltd (NASDAQ:SPCB)

Buoyed by a Q3 profit of $614,000, shares of Israel-based Supercom Ltd (NASDAQ:SPCB) are up almost 50% in morning trading and hovering around the $4 handle. On a per-share basis, the company said it had net income of $0.04 cents. Earnings, adjusted for one-time gains and costs, were $0.11 cents per share. The traditional and digital identity solutions provider posted revenue of $9.6 million for the period.

Supercom Ltd (NASDAQ:SPCB)

Supercom Ltd (NASDAQ:SPCB) develops and commercializes security software that cover markets including personal identity, machine-to-machine, cyber security device, payment, and connectivity products. Their clients include governments, as well as private and public organizations worldwide. Supercom offers MAGNA, a common platform for ID registries, e-passports, biometric visas, automated fingerprint identification systems, digitized driver’s licenses, and electronic voter registration and election management. It also offers its proprietary PureRF suite – a service based on radio-frequency identification (RFID) tag technology that was designed to identify, locate, track, monitor, count, and protect people and objects.

SPCB Stock

Shareholders will welcome the dramatic increase in revenues. Reported sales have been declining from their 2014 high of $29.7 million and were just $20 million for 2016. Similarly, earnings have also been declining. In 2012, earnings per share were posted at $0.75. That number has decreased each year and for 2016 the company posted a per share loss of (-$0.93)

That decline in sales and earnings led to SPCB shares losing almost 20% year-to-date. Today’s price action, should it continue to stay around $4, will establish a new 52-week high, besting the old $3.98 previous high established at the beginning of the year. The one-year consensus price target for SPCB stock is $4.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SPCB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

pSivida Corp. (NASDAQ:PSDV) Turns to Strategic Collaboration

pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. (NASDAQ:PSDV) was unchanged in Friday’s trading session, days after announcing a strategic collaboration with Nicox S.A. The collaboration seeks to enhance the development of a sustained-release drug that can lower intraocular pressure in patients with glaucoma or Ocular Hypertension.

pSivida Corp. (NASDAQ:PSDV)

PSDV Stock Performance

pSivida Corp. (NASDAQ:PSDV) shares are currently trading near all-time lows, the stock having been under immense selling pressure since June. Over the past four months, the stock has shed more than 50% in market value as it continues to trade in a downtrend. The company has since turned to strategic collaboration as it seeks to reinvigorate its prospects.

Nicox-pSivida Collaboration

Pursuant to the agreement, the two companies are to collaborate in the selection of NO-donating products from Nicox’s research portfolio, which are to be combined with pSivida’s sustained release drug technology.

“Combining this novel approach to IOP lowering with our bio erodible, a sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma,” said CEO, Nancy Lurker.

pSivida Corp. (NASDAQ:PSDV) has the responsibility of taking care of initial development activities of ocular insert formulations, for which it will receive undisclosed payments from Nicox. Under the terms of the agreement, the two companies may proceed with further development including non-clinical studies needed to generate pre-clinical data.

Nicox is to cater for any expenses that arise from incremental development activities for each product selected to progress into development. The two will negotiate a license agreement for any product that comes out of the collaboration.

Glaucoma Partnership

In addition, pSivida Corp. (NASDAQ:PSDV) has signed an agreement with a major pharmaceutical company for the development of two glaucoma drugs using its proprietary release technology. Under the terms of the agreement, the company is to receive, upfront payments of $750,000 for initial development. Additional payment totaling $200,000 could come into play depending on certain milestones.

“A key focus for pSivida during 2017 is to expand the number of development collaboration agreements with other drug manufacturers and this is the second such agreement during 2017. This agreement extends the strong working relationship between the two organizations,” Lurker in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSDV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.